Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $15.7 million.

  • Krystal Biotech's Cash from Financing Activities rose 54522.24% to $15.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.7 million, marking a year-over-year decrease of 6777.6%. This contributed to the annual value of $8.7 million for FY2025, which is 6777.6% down from last year.
  • Per Krystal Biotech's latest filing, its Cash from Financing Activities stood at $15.7 million for Q4 2025, which was up 54522.24% from $3.7 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Cash from Financing Activities ranged from a high of $202.1 million in Q4 2021 and a low of -$12.5 million during Q1 2025
  • Moreover, its 5-year median value for Cash from Financing Activities was $3.2 million (2022), whereas its average is $31.1 million.
  • In the last 5 years, Krystal Biotech's Cash from Financing Activities skyrocketed by 1552713.57% in 2022 and then plummeted by 21779.27% in 2025.
  • Krystal Biotech's Cash from Financing Activities (Quarter) stood at $202.1 million in 2021, then crashed by 98.48% to $3.1 million in 2022, then fell by 14.66% to $2.6 million in 2023, then fell by 7.29% to $2.4 million in 2024, then surged by 545.22% to $15.7 million in 2025.
  • Its Cash from Financing Activities stands at $15.7 million for Q4 2025, versus $3.7 million for Q3 2025 and $1.8 million for Q2 2025.